Biotechnology company NewcelX has announced the appointment of Professor Camillo Ricordi, a globally recognised figure in diabetes research, to its scientific advisory board. The move, confirmed today, 13 July 2026, is set to bolster NewcelX's strategic direction, particularly in its pursuit of advanced cell-based therapies for type 1 diabetes.
Professor Ricordi brings a wealth of experience, having pioneered significant advancements in islet transplantation, a procedure where insulin-producing cells are transferred from a donor pancreas into a person with type 1 diabetes. His extensive background in regenerative medicine and immunology aligns with NewcelX's mission to develop innovative solutions for chronic diseases.
The UK faces a significant challenge with diabetes, with official figures indicating that over 400,000 individuals are currently living with type 1 diabetes. This autoimmune condition requires lifelong insulin therapy and can lead to serious complications if not effectively managed. The NHS, guided by NICE recommendations, continuously explores new treatments and management strategies to improve patient outcomes and reduce the burden of the disease.
NewcelX's decision to integrate such a distinguished expert reflects a growing industry focus on harnessing cellular therapies to address the root causes of type 1 diabetes. The hope is that by leveraging cutting-edge research, companies like NewcelX can move closer to treatments that offer long-term solutions, potentially reducing the daily dependency on insulin injections for many patients.
The scientific advisory board plays a crucial role in guiding a biotechnology company's research and development pipeline, ensuring scientific rigour and strategic alignment with emerging therapeutic opportunities. Professor Ricordi's input is expected to be instrumental in shaping NewcelX's future projects and accelerating the translation of scientific discoveries into clinical applications.